Our findings are consistent with a recent meta-analysis showing that metformin and GLP-1 receptor agonists (GLP-1 RAs) can improve insulin sensitivity, reduce testosterone levels, and mitigate the risk of cardiovascular disease in women with PCOS [43]. This evidence concerns the gene GCG and cardiovascular disorder.